Overview

Apelin is an endogenous peptide hormone that acts as the primary ligand for the APJ receptor (APLNR), a G-protein coupled receptor widely distributed throughout the cardiovascular system, central nervous system, and peripheral tissues. Originally discovered in 1998, apelin exists in several active forms including apelin-13, apelin-17, and apelin-36, with apelin-13 being the most potent and commonly studied variant.

Research indicates that apelin plays crucial roles in cardiovascular homeostasis, glucose metabolism, fluid balance, and cellular energy production. The peptide demonstrates cardioprotective properties, supports mitochondrial function, and may offer therapeutic potential for conditions including heart failure, diabetes, obesity, and acute kidney injury.

Mechanism of Action

Apelin exerts its effects through binding to the APJ receptor, which triggers multiple intracellular signaling pathways including:

Cardiovascular Effects:

• Activation of nitric oxide synthase, leading to vasodilation and improved blood flow
• Enhancement of cardiac contractility through positive inotropic effects
• Regulation of blood pressure and vascular tone
• Promotion of angiogenesis through VEGF-independent pathways

Metabolic Effects:

• Improvement of insulin sensitivity and glucose uptake in skeletal muscle
• Enhancement of mitochondrial biogenesis and oxidative metabolism
• Regulation of adipocyte function and energy expenditure
• Modulation of pancreatic beta-cell function

Renoprotective Effects:

• Protection of renal tubular mitochondrial function during acute injury
• Reduction of oxidative stress and inflammation in kidney tissues
• Maintenance of glomerular filtration rate under stress conditions

Research Summary

Current research on apelin spans 10 significant publications and 5 clinical trials, with most evidence coming from preclinical studies. The peptide shows particular promise in cardiovascular disease, metabolic disorders, and organ protection.

Key Studies

Cardiovascular Applications: A 2023 comprehensive review in Biomedicine & Pharmacotherapy examined the therapeutic potential of apelin in cardiovascular disease, highlighting its role in heart failure, hypertension, and ischemic conditions. The authors noted apelin's unique ability to improve cardiac output while reducing afterload, making it an attractive therapeutic target.

Renal Protection: A 2021 study in Amino Acids demonstrated that apelin rescued acute kidney injury by protecting renal tubular mitochondrial function. The research showed significant improvements in mitochondrial respiration, reduced oxidative stress, and preserved kidney function in animal models of acute injury.

Cancer Research: Recent 2025 research in EMBO Molecular Medicine investigated apelin's role in cancer metastasis, finding that repression of specific apelin cleavage sites could provide an antimetastatic strategy in colorectal cancer. This highlights the complex role of apelin in disease states.

Metabolic Effects: A foundational 2011 study in Endocrine established the relationship between apelin, diabetes, and obesity, demonstrating the peptide's role in glucose homeostasis and adipose tissue function. Research showed improved insulin sensitivity and metabolic parameters in various disease models.

Receptor Characterization: Comprehensive 2014 research in Biochemistry and Cell Biology detailed the apelin receptor's physiology and cell signaling mechanisms, providing crucial understanding of how different apelin variants interact with their target receptor to produce therapeutic effects.

Dosage Guidelines

Human dosing protocols for apelin remain experimental, as most research has been conducted in preclinical models. Limited clinical trial data does not yet provide definitive dosing recommendations.

Research Considerations:

• Animal studies typically use doses ranging from 0.01-1.0 mg/kg
• Different apelin variants (apelin-13, -17, -36) may require different dosing
• Duration of effects appears to be relatively short, suggesting multiple daily doses may be needed
• Route of administration significantly affects bioavailability and duration

Safety Profile

The safety profile of apelin in humans remains largely unknown due to limited clinical data. Preclinical studies suggest generally good tolerability, but several important considerations exist:

Potential Side Effects:

• Hypotension due to vasodilatory effects
• Alterations in glucose levels
• Unknown effects on hormone regulation
• Potential impacts on fluid balance

Monitoring Recommendations:

• Regular blood pressure monitoring
• Glucose level assessment
• Cardiovascular function evaluation
• Kidney function tests

Special Populations: Apelin should not be used in pregnancy, breastfeeding, or individuals under 18 due to lack of safety data. Those with cardiovascular conditions should exercise particular caution due to the peptide's potent effects on heart function and blood pressure.

Stacking

Due to limited human research, stacking protocols for apelin remain theoretical. However, based on its mechanisms of action, several complementary approaches may be considered:

Cardiovascular Support:

• BPC-157: May provide complementary cardiovascular and tissue protective effects
• Potential synergy through different but related protective mechanisms

Metabolic Enhancement:

• Research suggests apelin's glucose regulatory effects could complement other metabolic peptides
• Careful monitoring would be essential due to potential additive effects on blood sugar

Organ Protection:

• The renoprotective and cardioprotective properties of apelin may complement other tissue-protective compounds
• Timing and dosing would require careful consideration

Important Note: All stacking considerations are theoretical pending human safety and efficacy data. Any combination use should only be considered under appropriate medical supervision with comprehensive monitoring protocols.

References

1. Bioactive peptide apelin rescues acute kidney injury by protecting the function of renal tubular mitochondria. (2021). Amino acids. DOI PubMed
2. Repression of apelin Furin cleavage sites provides antimetastatic strategy in colorectal cancer. (2025). EMBO molecular medicine. DOI PubMed
3. Therapeutic potential of apelin and Elabela in cardiovascular disease. (2023). Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. DOI PubMed
4. Apelin, diabetes, and obesity. (2011). Endocrine. DOI PubMed
5. The apelin receptor: physiology, pathology, cell signalling, and ligand modulation of a peptide-activated class A GPCR. (2014). Biochemistry and cell biology = Biochimie et biologie cellulaire. DOI PubMed
6. Apelin/APJ signaling in hypoxia-related diseases. (2015). Clinica chimica acta; international journal of clinical chemistry. DOI PubMed
7. Apelin/APJ system and cancer. (2016). Clinica chimica acta; international journal of clinical chemistry. DOI PubMed
8. Apelin is a novel islet peptide. (2010). Regulatory peptides. DOI PubMed
9. New adipokines. (2016). Annales d'endocrinologie. DOI PubMed
10. Serum Apelin Peptide Level in Hemodialysis Patients With Pulmonary Arterial Hypertension. (2018). Iranian journal of kidney diseases. PubMed